Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × rilotumumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5 Recurrence 2 Esophageal Neoplasms 2 Solitary Fibrous Tumor, Pleural 1 Small Cell Lung Carcinoma 1 Recurrent Squamous Cell Lung Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pleural Effusion, Malignant 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 MET Positive 1 Lung Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01443065 2020-11-17

MEGA

UNICANCER

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡